Zydus Lifesciences Limited

NSE ZYDUSLIFE.NS

Zydus Lifesciences Limited Price to Book Ratio (P/B) on January 14, 2025: 4.82

Zydus Lifesciences Limited Price to Book Ratio (P/B) is 4.82 on January 14, 2025, a 15.76% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.
  • Zydus Lifesciences Limited 52-week high Price to Book Ratio (P/B) is 6.56 on August 09, 2024, which is 36.20% above the current Price to Book Ratio (P/B).
  • Zydus Lifesciences Limited 52-week low Price to Book Ratio (P/B) is 4.09 on January 16, 2024, which is -15.08% below the current Price to Book Ratio (P/B).
  • Zydus Lifesciences Limited average Price to Book Ratio (P/B) for the last 52 weeks is 5.26.
Key data
Date Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield Price to Earnings Ratio (P/E)
Market news
Loading...
NSE: ZYDUSLIFE.NS

Zydus Lifesciences Limited

CEO Mr. Punit Patel
IPO Date July 1, 2002
Location India
Headquarters Zydus Corporate Park
Employees 26,921
Sector Health Care
Industries
Description

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, Europe, Latin America, the Asia Pacific, and Africa. The company operates in Pharmaceuticals and Consumer Products segments. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; consumer wellness products; and products in the therapeutic areas of pain management, neurology, dermatology, liver diseases, and other areas. The company also provides consumer wellness products, such as Complan; EverYuth, a range of skincare products; Nycil; Glucon-D glucose powder; Nutralite; Nutralite Doodhshakti, a portfolio of dairy products; and various other products. In addition, the company offers a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, ophthalmology, inflammation, rheumatology, hepatology, infectious disease, etc. Further, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is based in Ahmedabad, India.

Similar companies

INDUSTOWER.NS

Indus Towers Limited

USD 3.93

6.33%

SYNGENE.NS

Syngene International Limited

USD 9.56

0.73%

ALKEM.NS

Alkem Laboratories Limited

USD 60.83

0.86%

MOTHERSON.NS

Samvardhana Motherson International Limited

USD 1.68

4.32%

GLAND.NS

Gland Pharma Limited

USD 19.28

-1.41%

StockViz Staff

January 15, 2025

Any question? Send us an email